131 related articles for article (PubMed ID: 37983738)
1. Proton pump inhibitors and the risk of acute kidney injury in cancer patients receiving immune checkpoint inhibitors: A Danish population-based cohort study.
Munch PV; Nørgaard M; Heide-Jørgensen U; Jensen SK; Birn H; Christiansen CF
Int J Cancer; 2024 Apr; 154(7):1164-1173. PubMed ID: 37983738
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
[TBL] [Abstract][Full Text] [Related]
4. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors.
Baek YH; Kang EJ; Hong S; Park S; Kim JH; Shin JY
Int J Cancer; 2022 Apr; 150(8):1291-1300. PubMed ID: 34877670
[TBL] [Abstract][Full Text] [Related]
5. Use of proton pump inhibitors and macrolide antibiotics and risk of acute kidney injury: a self-controlled case series study.
Ikuta K; Nakagawa S; Yamawaki C; Itohara K; Hira D; Imai S; Yonezawa A; Nakagawa T; Sakuragi M; Sato N; Uchino E; Yanagita M; Terada T
BMC Nephrol; 2022 Nov; 23(1):383. PubMed ID: 36451129
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with immune check point inhibitors and acute kidney injury.
Valentin A; Møller AKH; Palshof JA; Broberg B; Gravesen E; Svane IM; Hansen D
Acta Oncol; 2023 Feb; 62(2):121-125. PubMed ID: 36755491
[TBL] [Abstract][Full Text] [Related]
7. Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: Systematic review and meta-analysis of real-world evidence.
Xie W; Xiao S; Li X; Huang J; Li G; Zhang Z
Eur J Intern Med; 2023 Sep; 115():88-95. PubMed ID: 37263805
[TBL] [Abstract][Full Text] [Related]
8. Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies.
Yang Y; George KC; Shang WF; Zeng R; Ge SW; Xu G
Drug Des Devel Ther; 2017; 11():1291-1299. PubMed ID: 28479851
[TBL] [Abstract][Full Text] [Related]
9. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
[TBL] [Abstract][Full Text] [Related]
10. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
[No Abstract] [Full Text] [Related]
11. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors.
Yan H; Tang M; Zhu W; Yang Y
Clin Exp Nephrol; 2023 Jul; 27(7):603-612. PubMed ID: 37014535
[TBL] [Abstract][Full Text] [Related]
13. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy.
Baker ML; Yamamoto Y; Perazella MA; Dizman N; Shirali AC; Hafez N; Weinstein J; Simonov M; Testani JM; Kluger HM; Cantley LG; Parikh CR; Wilson FP; Moledina DG
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35354588
[TBL] [Abstract][Full Text] [Related]
14. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study.
Liabeuf S; Lambert O; Metzger M; Hamroun A; Laville M; Laville SM; Frimat L; Pecoits-Filho R; Fouque D; Massy ZA; Jacquelinet C; Stengel B;
Br J Clin Pharmacol; 2021 Jul; 87(7):2967-2976. PubMed ID: 33368448
[TBL] [Abstract][Full Text] [Related]
15. Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study.
Zhou P; Liu B; Shen N; Fan X; Lu S; Kong Z; Gao Y; Lv Z; Wang R
Ren Fail; 2024 Dec; 46(1):2326186. PubMed ID: 38466161
[TBL] [Abstract][Full Text] [Related]
16. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
Chen G; Ning LJ; Qin Y; Zhao B; Mei D; Li XM
J Gastroenterol Hepatol; 2021 Jan; 36(1):156-162. PubMed ID: 32542684
[TBL] [Abstract][Full Text] [Related]
17. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
[TBL] [Abstract][Full Text] [Related]
18. The association between proton pump inhibitor use and risk of post-hospitalization acute kidney injury: a multicenter prospective matched cohort study.
Zhang Y; Ghahramani N; Razjouyan H; Ba DM; Chinchilli VM
BMC Nephrol; 2023 May; 24(1):150. PubMed ID: 37237361
[TBL] [Abstract][Full Text] [Related]
19. All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality.
Chen JJ; Lee TH; Kuo G; Yen CL; Lee CC; Chang CH; Tu KH; Chen YC; Fang JT; Hung CC; Yang CW; Chou WC; Chi CC; Tu YK; Yu Yang H
Clin Kidney J; 2024 Jan; 17(1):sfad292. PubMed ID: 38186874
[TBL] [Abstract][Full Text] [Related]
20. Self-controlled Case Series Study for Acute Kidney Injury after Starting Proton Pump Inhibitors or Potassium-Competitive Acid Blocker in Patients with Cancer Using a Large Claims Database.
Suzuki K; Watanabe A; Kiryu Y; Inoue E; Momo K
Biol Pharm Bull; 2024; 47(2):518-526. PubMed ID: 38403662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
